Should I Stay?

[anonymous]

Just didn't sign up to work for AZ

Do you understand?

 

[anonymous]

Understand.
Not a bad place to be.

 

[anonymous]

Clean label is guaranteed. Will be standard of care

 

[anonymous]

Clean label is guaranteed. Will be standard of care

Bullshit, you all are smoking crack at your circle jerk National Sales meeting! Second to market two years after the fact, sodium load, edema, and you didn’t even have that many CKD patients in your study! The smart ones have already left your company! Not to mention the fact every plan is going to have you on a prior auth for at least the first year! Best of luck!!! Right race, wrong horse!

 

[anonymous]

Lord help us....
But I am concerned.
Our boys across the pond barely mentioned zs-9 when dialogue about what a great match roxadustat will be on all those farxiga callpoints on nephrology. Wouldn't it seem that roxa is a nice match with zs-9 for cardio renal alignment.

 

[anonymous]

Lord help us....
But I am concerned.
Our boys across the pond barely mentioned zs-9 when dialogue about what a great match roxadustat will be on all those farxiga callpoints on nephrology. Wouldn't it seem that roxa is a nice match with zs-9 for cardio renal alignment.

Sorry #ericlong. Wake up from your dream!

 

[anonymous]

Ok, to the dumbass who suggested that the diabetes team calls on nephrology. Please read the label, nd creatinine clearance! They call on internal med and endocrinologists. It’s all about Roxa. zs9 is a place holder, won’t do much. Will be a dog to sell without much coverage, resources, marketing and big pharma metrics, approach won’t help you sell it. Renal is already under the umbrella of the entire devision. We are a subset to the devision. The culture is all about who stays and who goes. No one in leadership has any experience in this space, and no one on the ZS side has been or will be promoted. Not many real, honest questions were answered. What matters, is what happens in the next few months.

 

[anonymous]

Pay attention. This shit is happening. Results shared in EU re long term data are great. The small amounts of hypertension and edema will not effect the majority of the population. Our competition is not focused and the Relypsa organization is a complete mess. They are clueless.
AstraZeneca said its potential blockbuster hyperkalemia drug ZS-9 is back on track after the FDA rejected it in 2016 due to manufacturing issues at its Texas facility.

A decision by the U.S. regulatory agency on the drug is expected in the first half of 2018, the company said in its 2017 year-end earnings report. During a conference call with analysts, the company said there was “encouraging news for ZS-9 in both the U.S. and the EU.”

 

[anonymous]

AstraZeneca said its potential blockbuster hyperkalemia drug ZS-9 is back on track after the FDA rejected it in 2016 due to manufacturing issues at its Texas facility.

A decision by the U.S. regulatory agency on the drug is expected in the first half of 2018, the company said in its 2017 year-end earnings report. During a conference call with analysts, the company said there was “encouraging news for ZS-9 in both the U.S. and the EU.”

First half of 2018. This is happening! Know that our supposed competitors company is badly run and scattered. The 12 month data is good and providers want another option. This won’t be easy but it will b good!

 

[anonymous]

AstraZeneca said its potential blockbuster hyperkalemia drug ZS-9 is back on track after the FDA rejected it in 2016 due to manufacturing issues at its Texas facility.

A decision by the U.S. regulatory agency on the drug is expected in the first half of 2018, the company said in its 2017 year-end earnings report. During a conference call with analysts, the company said there was “encouraging news for ZS-9 in both the U.S. and the EU.”

First half of 2018. This is happening! Know that our supposed competitors company is badly run and scattered. The 12 month data is good and providers want another option. This won’t be easy but it will b good!

Bullshit, your data sucks on the long term trial (sure no one is worried about edema , keep telling yourselves that!) All of your KOL’s have now committed to Veltassa! Good luck with the cardiologists you’ve been calling on for two years, they all want outcomes data! Choke on your diamond dusted salt bomb! #rightracewronghorse

 

[anonymous]

Bullshit, your data sucks on the long term trial (sure no one is worried about edema , keep telling yourselves that!) All of your KOL’s have now committed to Veltassa! Good luck with the cardiologists you’ve been calling on for two years, they all want outcomes data! Choke on your diamond dusted salt bomb! #rightracewronghorse

#ericlong wake up from your dream

 

[anonymous]

Is the ZS sales force staying intact?

 

[anonymous]

It's all going to fall apart.. It's just a matter of time

 

[anonymous]

I love seeing all the Valtessa turds trolling these boards because they are scared and know that ZS9 means their crappy excuse for a product is screwed. Good luck turds.

 

[anonymous]

Bullshit, you all are smoking crack at your circle jerk National Sales meeting! Second to market two years after the fact, sodium load, edema, and you didn’t even have that many CKD patients in your study! The smart ones have already left your company! Not to mention the fact every plan is going to have you on a prior auth for at least the first year! Best of luck!!! Right race, wrong horse!

Showing your cards, not a good look. You know you are screwed. Gooooooood luck. You're going to need it while pushing that lazy attempt at a crappy polystyrene sulfonate reboot. It's easy to talk big when you don't have any competition. When ZS9 launches you'll get whiplash from how quickly things change for you.

 

[anonymous]

Showing your cards, not a good look. You know you are screwed. Gooooooood luck. You're going to need it while pushing that lazy attempt at a crappy polystyrene sulfonate reboot. It's easy to talk big when you don't have any competition. When ZS9 launches you'll get whiplash from how quickly things change for you.

“Polystyrene sulfonate reboot”. Hmmm. Yeah. Keep on with that. Your onset data may give you hospital business and replace some SPS. Is that enough for you to keep your grossly overpaid position? Don’t think so, not even with a somewhat “clean” label.

 

[anonymous]

“Polystyrene sulfonate reboot”. Hmmm. Yeah. Keep on with that. Your onset data may give you hospital business and replace some SPS. Is that enough for you to keep your grossly overpaid position? Don’t think so, not even with a somewhat “clean” label.

I think you mean site of action, onset, dosing, discontinuation, and safety/AE data. You know. All of the benefits over patiromer. A highly specific, targeted compound vs a Hoover vacuum "suck up any ol' cation" approach. No brainer.

 

[anonymous]

all you needs to do is launch ZS in a traditional pharmacy distribution model and have a dedicated hospital sales force =game over for RLYP. field is already divided over the spec pharmacy reporting debacle , not to mention crap coverage and leadership that is quickly losing credibility.

 

[anonymous]

all you needs to do is launch ZS in a traditional pharmacy distribution model and have a dedicated hospital sales force =game over for RLYP. field is already divided over the spec pharmacy reporting debacle , not to mention crap coverage and leadership that is quickly losing credibility.

This exactly. RLYP is on borrowed time.

 

[anonymous]

I think you mean site of action, onset, dosing, discontinuation, and safety/AE data. You know. All of the benefits over patiromer. A highly specific, targeted compound vs a Hoover vacuum "suck up any ol' cation" approach. No brainer.

Only if you cherry pick your data. When looked at as a whole, huge difference in AEs, etc. You will get one time/ short time use. Again, not enough to justify your paycheck.